MISSISSAUGA, ON, July 7, 2017 /CNW/ - Further to the recent recall of RestoraLAX® 45+10 Value Packs, Bayer Inc. has voluntarily expanded the recall to include specific lots of RestoraLAX 30+7 Bonus Packs sold at retailers across Canada. Specific lots of RestoraLAX 30+7 Bonus Packs have been found to contain poorly soluble product deposits that in rare cases could pose a risk when swallowed.
RestoraLAX is a laxative used to relieve occasional constipation and irregularity.
Consumers who believe they have either product should stop using it immediately and return the product as soon as possible. Once returned, consumers will receive a full refund.
Bayer is working closely with Health Canada and our Canadian retail partners to ensure that consumers are notified immediately and all impacted inventory is removed from store shelves and quarantined as soon as possible.
This recall is only for the Canadian market. The following lots of RestoraLAX 30+7 Bonus Packs are impacted: 6G03PU, 6G02PU, 5M09PU, 6E25PU, 5M03PU. As this issue is associated with a packaging process specific to the RestoraLAX® 45+10 Value Packs and the RestoraLAX 30+7 Bonus Packs, no other RestoraLAX packaging formats are impacted.
What should consumers do:
Consumers who believe they are in possession of RestoraLAX 45+10 Value Pack from Costco (excluding Quebec) or a RestoraLAX 30+7 Bonus Pack are asked to stop using it immediately and return the product as soon as possible for a refund.
For more information:
To report an adverse event, product complaint or have questions about this recall, please contact Bayer at 1-800-265-7382 or visit restoralax.ca. If you have a medical concern, please speak with your health care provider.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.ca.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE Bayer Inc.
Media Contact: Corporate Communications: 905-282-5541, E-mail: [email protected]
Also from this source
Share this article